Study of Pembrolizumab and Radiotherapy in Liver Cancer

Stopped The study was stopped due to the shift in systemic treatment paradigm for HCC precluding further enrolment.

Conditions

• Hepatocellular Carcinoma

Interventions

• DRUG: Pembrolizumab
• RADIATION: Stereotactic Body Radiotherapy (SBRT)

Sponsor

University Health Network, Toronto